Advances in parasitology. history, hiatus and hubris. Part A] /

Advances in parasitology. history, hiatus and hubris. Part A] / Volume eighty, [The epidemiology of plasmodium vivax :

First published in 1963, Advances in Parasitology contains comprehensive and up-to-date reviews in all areas of interest in contemporary parasitology. Advances in Parasitology includes medical studies on parasites of major influence, such as Plasmodium falciparum and trypanosomes. The series also co...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Άλλοι συγγραφείς: Hay, S. I. (Simon I.), Price, Ric, Baird, J. Kevin
Μορφή: Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Kidlington, Oxford : Elsevier, 2012.
Έκδοση:1st ed.
Σειρά:Advances in parasitology ; v. 80.
Θέματα:
Parasitology.
SCIENCE > Life Sciences > Zoology > General.
Electronic books.
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • Front Cover; Series Editors; Editorial Board; Advances in Parasitology; Copyright; Contents; Contributors; Preface; Chapter One
  • The Global Public Health Significance of Plasmodium vivax;?1. INTRODUCTION;?2. THE GLOBAL DISTRIBUTION OF P. VIVAX INFECTIONS;?3. SPATIAL DISTRIBUTION OF P. VIVAX MALARIA, POPULATIONS AT RISK AND ITS VECTORS;?4. REGIONAL SUMMARIES OF THE PUBLIC HEALTH SIGNIFICANCE OF P. VIVAX MALARIA;?5. DISCUSSION;?6. METHODS;?LIST OF ABBREVIATIONS; ACKNOWLEDGEMENTS; REFERENCES; Chapter Two
  • Relapse;?1. INTRODUCTION;?2. HISTORY;?3. PHENOTYPIC VARIATION IN P. VIVAX.
  • 4. RELAPSE DETERMINANTS?5. GEOGRAPHIC DISTRIBUTION OF RELAPSE PHENOTYPES;?6. THE EFFECTS OF AGE AND IMMUNITY ON RELAPSE;?7. DRUG EFFECTS ON RELAPSE;?8. VIVAX MALARIA FOLLOWING FALCIPARUM MALARIA;?9. THE PERIODICITY OF RELAPSE;?10. IMPLICATIONS FOR EPIDEMIOLOGICAL ASSESSMENT; ACKNOWLEDGEMENTS; REFERENCES; Chapter Three
  • Plasmodium vivax: Clinical Spectrum, Risk Factors and Pathogenesis;?1. INTRODUCTION;?2. PRE-PATENT AND INCUBATION PERIODS;?3. SYMPTOMS AND SIGNS OF VIVAX MALARIA;?4. CLINICAL ILLNESS REQUIRING HOSPITALISATION;?5. SEVERE MALARIA;?6. RISK OF SEVERE DISEASE AND DEATH.
  • 7. VULNERABLE GROUPS?8. SPECIFIC CLINICAL MANIFESTATIONS OF SEVERE VIVAX MALARIA;?9. SEVERE AND FATAL DISEASE RESULTING FROM TREATMENT WITH PRIMAQUINE;?10. RISK FACTORS FOR UNCOMPLICATED AND SEVERE VIVAX MALARIA;?11. PATHOPHYSIOLOGY OF DISEASE IN VIVAX MALARIA;?12. CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; Chapter Four
  • Diagnosis and Treatment of Plasmodium vivax Malaria;?1. INTRODUCTION;?2. CHEMOTHERAPEUTICS TERMINOLOGY;?3. HISTORICAL PERSPECTIVES;?4. CHEMOPROPHYLAXIS AGAINST VIVAX MALARIA;?5. DIAGNOSIS OF VIVAX MALARIA;?6. TREATMENT OF UNCOMPLICATED VIVAX MALARIA.
  • 7. TREATMENT OF SEVERE AND COMPLICATED VIVAX MALARIA?8. EVALUATING DRUG RESISTANCE IN VIVAX MALARIA;?9. RESEARCH AND DEVELOPMENT URGENCIES;?10. SUMMARY; REFERENCES; Chapter Five
  • Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria;?1. INTRODUCTION;?2. TRANSMISSION OF P. VIVAX;?3. REDUCING P. VIVAX TRANSMISSION BY TREATING SYMPTOMATIC DISEASE;?4. REDUCING P. VIVAX TRANSMISSION USING MASS DRUG ADMINISTRATION;?5. CONCLUSIONS; REFERENCES; Chapter Six
  • Control and Elimination of Plasmodium vivax;?1. WHY CONTROLLING P. VIVAX IS DIFFICULT.
  • 2. ESTABLISHED ANTI-TRANSMISSION MEASURES?3. DRUGS FOR CONTROL OF RELAPSING MALARIA;?4. DIFFICULTY GOING FROM LOW TO NO MALARIA TRANSMISSION;?5. SURVEILLANCE AS KEY INTERVENTION FOR MALARIA ELIMINATION;?6. PROBLEMS OF MALARIA REINTRODUCTION INTO ELIMINATED AREAS;?7. PROSPECTS FOR IMPROVED DRUGS FOR CONTROL/ELIMINATION;?8. PROSPECTS FOR IMPROVED ANTI-TRANSMISSION MEASURES;?9. CONCLUSIONS; ACKNOWLEDGEMENTS; REFERENCES; INDEX.

Παρόμοια τεκμήρια